Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

American journal of preventive cardiology·2022
Same author

Factors predicting cardiac arrest in acute coronary syndrome patients under 50: A state-wide angiographic and forensic evaluation of outcomes.

Resuscitation·2022
Same author

Biological Sensing of Nitric Oxide in Macrophages and Atherosclerosis Using a Ruthenium-Based Sensor.

Biomedicines·2022
Same author

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.

International journal of molecular sciences·2022
Same author

Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation.

PharmacoEconomics·2022
Same author

Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.

Cardiovascular diabetology·2022
Same journal

Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.

Current cardiology reports·2026
Same journal

Transcriptome Reprogramming in Heart Failure: The Hidden Splicing Code.

Current cardiology reports·2026
Same journal

Diagnosis and Management of Loeys-Dietz Syndrome: Evidence Gaps and Future Directions.

Current cardiology reports·2026
Same journal

Correction: Heart Disease in Older Women: Unique Challenges in Diagnosis and Management.

Current cardiology reports·2026
Same journal

Beyond the ICD: Navigating Ventricular Tachycardia Suppression Strategies in the Modern Era.

Current cardiology reports·2026
Same journal

Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics.

Current cardiology reports·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Evacetrapib.

Stephen J Nicholls1

  • 1Departments of Cardiovascular Medicine and Cell Biology and the Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. nichols1@ccf.org

Current Cardiology Reports
|February 25, 2012
PubMed
Summary
This summary is machine-generated.

Novel cholesteryl ester transfer protein (CETP) inhibitors, like evacetrapib, aim to increase high-density lipoprotein cholesterol (HDL-C). Early studies suggest evacetrapib favorably impacts lipids without adverse effects, offering potential cardiovascular benefits.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: May 24, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Lipid Metabolism

Background:

  • Therapeutic strategies targeting elevated high-density lipoprotein cholesterol (HDL-C) are of significant interest.
  • Cholesteryl ester transfer protein (CETP) inhibitors are designed to increase HDL-C levels beyond current lipid-modifying therapies.
  • Previous CETP inhibitor trials (e.g., torcetrapib) faced setbacks due to adverse clinical outcomes, highlighting the need for safer agents.

Purpose of the Study:

  • To evaluate the efficacy and safety of evacetrapib, a novel CETP inhibitor.
  • To assess the impact of evacetrapib on plasma lipids and potential off-target effects.

Main Methods:

  • Clinical evaluation of evacetrapib, a novel CETP inhibitor.
  • Assessment of plasma lipid profiles.
  • Monitoring for adverse effects on blood pressure and mineralocorticoid activity.

Main Results:

  • Evacetrapib demonstrated favorable effects on plasma lipid levels in early clinical evaluation.
  • No adverse effects on blood pressure were observed.
  • No impact on mineralocorticoid activity was detected.

Conclusions:

  • Evacetrapib shows promise as a novel CETP inhibitor with a potentially improved safety profile compared to earlier agents.
  • Further investigation is required to determine the long-term cardiovascular outcomes associated with evacetrapib treatment.